Why the study?
Do specific pulmonary hypertension targeted therapies improve clinical and hemodynamic outcomes in patients with chronic heart failure and post-capillary pulmonary hypertension?
Do specific pulmonary hypertension targeted therapies improve clinical and hemodynamic outcomes in patients with chronic heart failure and post-capillary pulmonary hypertension?
Answers are grounded in this paper and cite their sources.
Instead of using specific vasodilators that may worsen outcomes in post-capillary pulmonary hypertension, therapeutic management should remain focused on blood volume optimization, reducing left atrial pressure, and improving right ventricular coupling.
Pulmonary hypertension (PH) is a common and severe complication of heart failure (HF). Consequently, HF is the leading cause of PH. For many years, specialists have attempted to better understand the pathophysiology of PH in HF, to define its prevalence and its impact on prognosis in order to improve the therapeutic management of these patients. Nowadays, despite the recent guidelines published on the subject, several points remain unclear or debated, and until now, no study has demonstrated the efficacy of any treatment. The aim of this review is to report the evolution of the concepts on post-capillary PH (diagnosis, prevalence, prognosis, and therapeutics). The main issues are raised, focusing especially on the link between structural alterations and haemodynamic abnormalities, to discuss the possible reasons for treatment failures and future potential targets.
No takes yet. Share an insight, caveat, or question.
Berthelot et al. (2018) conducted a review in Chronic Heart Failure with Pulmonary Hypertension. Pulmonary hypertension targeted therapies (e.g., PDE5 inhibitors, endothelin receptor antagonists) was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: